Umecrine Cognition Ab

Alzecure Pharma Ab

Nicolaas Schipper

Thomas Meijer

Magnus Doverskog

Paul Alhadeff

Maja Johansson

Bo Lassen

Annika Gripenhall

Eva Maria Sjöström

Johanna Haglund

Märta Segerdahl

The present invention is directed to a novel pharmaceutical formulation comprising 3&#x3b1;-ethynyl-3&#x3b2;-hydroxyandrostan-17-one oxime in an amount of 0.1-10% by weight of the total weight of the composition; and a vehicle comprising (a) 45-100% of a monoester; (b) optionally up to 51% of a diester; and (c) optionally up to about 10% of a triester. Also claimed is a method for the treatment of medical conditions such as hypersomnia and hepatic encephalopathy by the use of a pharmaceutical formulation as claimed.

Pharmaceutical formulation of 3-alpha-ethynyl-3-beta-hydroxyandrostan-17-one oxime

The present invention is directed to a novel pharmaceutical formulation comprising 3&#x3b1;-ethynyl-3&#x3b2;-hydroxyandrostan-17-one oxime in an amount of 0.1-10% by weight of the total weight of the composition; and a vehicle comprising (a) 45-100% of a monoester; (b) optionally up to 51% of a diester; and (c) optionally up to about 10% of a triester. Also claimed is a method for the treatment of medical conditions such as hypersomnia and hepathic encephalopathy by the use of a pharmaceutical formulation as claimed.

Pharmaceutical formulation of 3&#x3b1;-ethynyl-3&#x3b2;-hydroxyandrostan-17-one oxime

Growing community of inventors

Ronninge, Sweden

Nicolaas Schipper